The fibronectin attachment protein of bacillus Calmette-Guerin (BCG) mediates antitumor activity

Cancer Immunology, Immunotherapy

Volumn 57, Issue 4, 2008, Pages 573-579

  Sinn, Haley W ^a   Elzey, Bennett D ^a   Jensen, Robert J ^a   Zhao, Xiuqin ^b   Zhao, Weicheng ^c   Ratliff, Timothy L ^a  

^a UNIVERSITY OF IOWA   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; FIBRONECTIN; PROTEIN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL INFECTION; BLADDER CANCER; CONTROLLED STUDY; DRUG ACTIVITY; IMMUNOGENICITY; MOUSE; MYCOBACTERIUM; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BCG VACCINE; FEMALE; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; OLIGOPEPTIDES; RECOMBINANT PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 38649101902     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0397-x     Document Type: Article

References (41)

1. Becich MJ, Carroll S, Ratliff TL (1991) Internalization of bacille Calmette-Guerin by bladder tumor cells. J Urol 145:1316-1324
2. Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL (1987) Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 137:220-224
3. Chin JL, Kadhim SA, Batislam E, Karlik SJ, Garcia BM, Nickel JC, Morales A (1996) Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. J Urol 156:1189-1193
4. Donat SM, North A, Dalbagni G, Herr HW (2004) Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. J Urol 171:636-639
5. Filion MC, Lepicier P, Morales A, Phillips NC (1999) Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells. Br J Cancer 79:229-235
6. Flamm J, Donner G, Bucher A, Holtl W, Albrecht W, Havelec L (1994) Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe A 33:138-143
7. Herr HW, Wartinger DD, Fair WR, Oettgen HF (1992) Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol 147:1020-1023
8. Horn C, Namane A, Pescher P, Riviere M, Romain F, Puzo G, Barzu O, Marchal G (1999) Decreased capacity of recombinant 45/47-kDa molecules (Apa) of Mycobacterium tuberculosis to stimulate T lymphocyte responses related to changes in their mannosylation pattern. J Biol Chem 274:32023-32030
9. Hudson MA, Brown EJ, Ritchey JK, Ratliff TL (1991) Modulation of fibronectin-mediated bacillus Calmette-Guerin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res 51:3726-3732
10. Jackson AM, Alexandroff AB, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S, Chisholm GD, James K (1995) Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 99:369-375
11. Jurincic-Winkler C, Engelmann U, Beuth J, Klippel KF (1995) Efficacy of local Bacillus Calmette-Guerin treatment in superficial bladder cancer relapsing under Keyhole-Limpet Hemocyanin immunotherapy. Zentralbl Bakteriol 282:409-415
12. Jurincic-Winkler CD, Metz KA, Beuth J, Klippel KF (2000) Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study. Eur Urol 37(Suppl 3):45-49
13. Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL (1990) Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85:62-67
14. Kuroda K, Brown EJ, Telle WB, Russell DG, Ratliff TL (1993) Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest 91:69-76
15. Lamm DL, Reichert DF, Harris SC, Lucio RM (1982) Immunotherapy of murine transitional cell carcinoma. J Urol 128:1104-1108
16. Lamm DL (1992) Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 19:565-572
17. Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne FM (1992) Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147:596-600
18. Lamm DL, DeHaven JI, Riggs DR, Ebert RF (1993) Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH). J Urol 149:648-652
19. Lamm DL (1995) BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology (Williston Park) 9:947-952, discussion 955-965
20. Laqueyrerie A, Militzer P, Romain F, Eiglmeier K, Cole S, Marchal G (1995) Cloning, sequencing, and expression of the apa gene coding for the Mycobacterium tuberculosis 45/47-kilodalton secreted antigen complex. Infect Immun 63:4003-4010
21. Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O'Donnell MA, Griffith TS (2004) Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 64:3386-3390
22. Morales A, Eidinger D (1976) Bacillus Calmette-Guerin in the treatment of adenocarcinoma of the kidney. J Urol 115:377-380
23. Morales A, Chin JL, Ramsey EW (2001) Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol 166:1633-1637; discussion 1637-1638
24. Nadler R, Luo Y, Zhao W, Ritchey JK, Austin JC, Cohen MB, O'Donnell MA, Ratliff TL (2003) Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity. Clin Exp Immunol 131:206-216
25. O'Donnell MA, Boehle A (2006) Treatment options for BCG failures. World J Urol 24(5):481-487
26. Olsson CA, Chute R, Rao CN (1974) Immunologic reduction of bladder cancer recurrence rate. J Urol 111:173-176
27. Pang AS, Morales A (1982) BCG induced murine peritoneal exudate cells: cytotoxic activity against a syngeneic bladder tumor cell line. J Urol 127:1225-1229
28. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1990) Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 144:1248-1251
29. Ratliff TL, Gillen D, Catalona WJ (1987) Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 137:155-158
30. Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ (1993) T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150:1018-1023
31. Reader S, Menard S, Filion B, Filion MC, Phillips NC (2001) Pro-apoptotic and immunomodulatory activity of a mycobacterial cell wall-DNA complex towards LNCaP prostate cancer cells. Prostate 49:155-165
32. Recker F, Rubben H (1989) Variation of the immunosystem by ciclosporin and keyhole-limpet hemocyanin-are there effects on chemically induced bladder carcinoma? Urol Int 44:77-80
33. Sanger C, Busche A, Bentien G, Spallek R, Jonas F, Bohle A, Singh M, Brandau S (2004) Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer. BMC Cancer 4:86
34. Schorey JS, Holsti MA, Ratliff TL, Allen PM, Brown EJ (1996) Characterization of the fibronectin-attachment protein of Mycobacterium avium reveals a fibronectin-binding motif conserved among mycobacteria. Mol Microbiol 21:321-329
35. Shapiro A, Ratliff TL, Oakley DM, Catalona WJ (1983) Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guerin and its correlation with Bacillus Calmette-Guerin viability and natural killer cell activity. Cancer Res 43:1611-1615
36. Suttmann H, Riemensberger J, Bentien G, Schmaltz D, Stockle M, Jocham D, Bohle A, Brandau S (2006) Neutrophil granulocytes are required for effective bacillus calmette-guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 66:8250-8257
37. Swerdlow RD, Ratliff TL, La Regina M, Ritchey JK, Ebert RF (1994) Immunotherapy with keyhole limpet hemocyanin: efficacy and safety in the MB-49 intravesical murine bladder tumor model. J Urol 151:1718-1722
38. Swerdlow RD, Ebert RF, Lee P, Bonaventura C, Miller KI (1996) Keyhole limpet hemocyanin: structural and functional characterization of two different subunits and multimers. Comp Biochem Physiol B Biochem Mol Biol 113:537-548
39. Vordermeier HM, Coombes AG, Jenkins P, McGee JP, O'Hagan DT, Davis SS, Singh M (1995) Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. Vaccine 13:1576-1582
40. Zhao W, Schorey JS, Groger R, Allen PM, Brown EJ, Ratliff TL (1999) Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP. J Biol Chem 274:4521-4526
41. Zhao W, Schorey JS, Bong-Mastek M, Ritchey J, Brown EJ, Ratliff TL (2000) Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 86:83-88